CAS
ACHL

Coppell Advisory Solutions’s Achilles Therapeutics ACHL Stock Holding History

Coppell Advisory Solutions’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,000
Closed -$5.56K – 1884
2023
Q3 		$5.56K Buy
+1,000
New +$951 ﹤0.01% 703

Other funds holding ACHL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FA
Forefront Analytics West Conshohocken, Pennsylvania $110M AUM 18.54% 1-Year Est. Return

Coppell Advisory Solutions's ACHL Position: Q4 2023 in Review

Coppell Advisory Solutions sold out of Achilles Therapeutics (ACHL) in Q4 2023, closing a stake of 1,000 shares — an estimated $5.56K sold.

Coppell Advisory Solutions first reported a position in ACHL in Q3 2023 and held it in 1 quarter. The position peaked at $5.56K in Q3 2023. 20 funds tracked by Wall St. Rank hold ACHL as of Q4 2023.

  • Coppell Advisory Solutions reported no remaining Achilles Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Coppell Advisory Solutions sold 1,000 Achilles Therapeutics shares in Q4 2023, an estimated $5.56K.
  • Coppell Advisory Solutions first reported a position in Achilles Therapeutics in Q3 2023 and held it in 1 quarter.
  • Coppell Advisory Solutions's Achilles Therapeutics position peaked at $5.56K in Q3 2023.
  • 20 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q4 2023.

Based on Coppell Advisory Solutions's 13F filing for Q4 2023, filed 14 Feb 2024.